Systemic Chemoprevention

  • Stephen Shumack
Part of the Cancer Treatment and Research book series (CTAR, volume 146)

Cutaneous neoplasms in organ transplant recipients (OTR) have traditionally been managed by early detection and treatment. Prevention is also a key factor in managing these patients, and to date this has largely been achieved through education, sun avoidance measures, and early detection with regular clinical reviews. Lately, systemic chemoprevention has emerged as an important modality for treatment whereby clinicians can hope to reduce and/or delay the development of cutaneous neoplasms in these patients.


Skin Cancer Basal Cell Carcinoma Renal Transplant Recipient Actinic Keratosis Organ Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acetretin. Br J Dermatol 1999; 140:656–60.PubMedCrossRefGoogle Scholar
  2. 2.
    Nguyen EQH, Wolverton SE. Systemic retinoids. In: Wolverton SE (ed) Comprehensive Dermatologic Drug Therapy. Philadelphia: Saunders, 2001:269–310.Google Scholar
  3. 3.
    Shuttleworth D, Marks R, Griffin PJA et al. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988; 68:717–24.PubMedGoogle Scholar
  4. 4.
    Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomised controlled trials. Br J Dermatol 2005; 152:518–23.PubMedCrossRefGoogle Scholar
  5. 5.
    George R, Weigtman W, Russ GR et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Aust J Dermatol 2002; 43:269–73.CrossRefGoogle Scholar
  6. 6.
    Bouwes Bavinck JN, Tieben LM, van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic lesions during acitretin therapy in renal transplant recipients: a double-blind placebo controlled study. J Clin Oncol 1995; 1933–8.Google Scholar
  7. 7.
    de Sevaux RGL, Smit JV, de Jong EMGJ et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomised trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49:407–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Harwood CA, Leedham-Green M, Leigh IM et al. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients. Arch Dermatol. 2005; 141: 456–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Otley C, Stasko T, Tope W et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006; 32:562–68.PubMedCrossRefGoogle Scholar
  10. 10.
    Kovach BT, Murphy G, Otley CC et al. Oral retinoids for chemoprevention of skin cancers in organ transplant recipients: results of a survey. Transplant Proc 2006; 38:1366–68.PubMedCrossRefGoogle Scholar
  11. 11.
    Luan FL, Hojo M, Maluccio M et al. Rapamycin blocks tumour progression: unlinking immunosuppression from antitumour efficacy. Transplantation 2002; 73:1565.PubMedCrossRefGoogle Scholar
  12. 12.
    Matthew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446–9.CrossRefGoogle Scholar
  13. 13.
    Kahan B, Knight R, Schoenberg L et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35:25S.PubMedCrossRefGoogle Scholar
  14. 14.
    Frieling UM, Schaumberg DA, Kupper TS et al. A randomized, 12 year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician’s health study. Arch Dermatol 2000; 136:245–6.CrossRefGoogle Scholar
  15. 15.
    Green A, Williams G, Neale R et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Stephen Shumack
    • 1
  1. 1.The St. George Dermatology and Skin Cancer Center, KogarahSydneyAustralia

Personalised recommendations